Comorbidity

Alexandria Real Estate Equities, Inc. Drives Forward Its Action- and Solutions-Oriented Corporate Responsibility Initiatives Aimed at Prioritizing the Staggering Mental Health Crisis During Mental Health Awareness Month

Retrieved on: 
星期一, 五月 6, 2024
FDA, DSM-IV codes, Comorbidity, Fentanyl, Investment, Risk, Mental Health Awareness Month, Policy, Health, Heart, Trauma, Diabetes, Partnership, Doctor of Philosophy, Alexandria Real Estate Equities, Depression, PPP, Drug overdose, Suicide, Navy, AAA, Military personnel, Ageing, Attention, Obesity, Mental, Injury, Verily, Science, Patient, Mental health, Addiction, Veteran, Biomarker, Government, Biogen, Anxiety, Therapy, Nursing

PASADENA, Calif., May 6, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, is leveraging its unique position at the vanguard and heart of the $5 trillion secularly growing life science industry and coalescing its world-class life science and healthcare networks to drive forward action- and solutions-oriented corporate responsibility initiatives aimed at prioritizing the devastating and pervasive mental health crisis. During Mental Health Awareness Month, a time dedicated nationally to increase awareness of the challenges faced by millions of Americans living with mental health conditions, Alexandria reaffirms its mission-critical goals to meaningfully address the urgent need to (1) break the stigma around mental illness and addiction, (2) promote mental health as essential to overall health and (3) help accelerate the development of innovative new treatments.

Key Points: 
  • "During Mental Health Awareness Month, we call for increased attention and policy action at the federal, state and local levels to transform the way we diagnose, treat and discuss mental illness.
  • Since 2010, Alexandria has been partnering with the Navy SEAL Foundation and enabling it to meet the specific mental health needs of these elite warriors.
  • Never has it been more essential to recognize the importance of mental health to overall health.
  • If you or someone you know is in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline.

Heatwaves Hit Harder for People with Disabilities: A Pusan National University Study Finds Increased Emergency Visits

Retrieved on: 
星期三, 四月 17, 2024
Public, Climate change, Comorbidity, Heat, Risk, Hospital, Disability, Health, Vision, IPCC, Research, The Lancet, Sustainable Development Goals, Disability studies, Notifiable disease, Temperature, Ageing, Pusan National University, Lancet, Person, Nursing

Amid these concerns, the Intergovernmental Panel on Climate Change (IPCC) warns that heatwaves increase in intensity, frequency, and duration with every 0.5°C increase in temperature .

Key Points: 
  • Amid these concerns, the Intergovernmental Panel on Climate Change (IPCC) warns that heatwaves increase in intensity, frequency, and duration with every 0.5°C increase in temperature .
  • Despite these observations, however, there are limited studies on the impact of high temperatures on the health of people with disabilities.
  • Their study, published in the journal The Lancet Planetary Health, reveals disparities in admissions and medical expenses for individuals with disabilities and those without disabilities.
  • Title of original paper: Association between heat and hospitalizations in persons with disabilities: a nationwide case-crossover study

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Retrieved on: 
星期四, 四月 11, 2024
Pelvis, FDA, Safety, Weight, BMC, Comorbidity, Facial muscles, LM, Conference call, BMI, Testosterone, Weight loss, Rib, DEXA, Webcast, Obesity, Week, Dyslipidemia, Type 2 diabetes, Body composition, Patient, Hypertension, 3rd millennium, Dietary supplement

Furthermore LPCN 2401 could help to attenuate collateral fattening and rebound fat/weight "overshoot" associated with discontinuation of GLP-1/GIP agonists.

Key Points: 
  • Furthermore LPCN 2401 could help to attenuate collateral fattening and rebound fat/weight "overshoot" associated with discontinuation of GLP-1/GIP agonists.
  • We look forward to meeting with the FDA to discuss the further development of LPCN 2401 as an aid to weight management interventions."
  • Analyses of body composition parameters, including prespecified endpoints of whole body LM and whole-body FM, are reported in the table below.
  • An overall improvement in body composition is evidenced by substantial decrease in the fat mass to lean mass ratio.

THE DERMATOLOGY FOUNDATION AND SKIN OF COLOR SOCIETY BESTOW THE FIRST-EVER SANOFI AND REGENERON DIVERSITY, EQUITY, AND INCLUSION MID-CAREER AWARD ON DONALD A. GLASS II, MD, PhD, FAAD

Retrieved on: 
星期二, 三月 19, 2024
SOCS, Autoimmunity, University, Glass, Regeneron Pharmaceuticals, Associate, Health equity, Genetics, Patient, DF, Research, Diversity, American Academy, Doctor of Philosophy, MBA, Skin, University of Massachusetts, MPH, Comorbidity, FAAD, Bangladesh Technical Education Board, DEI, Vitiligo, Medicine, Pharmaceutical industry

CHICAGO, March 19, 2024 /PRNewswire/ -- The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Donald A. Glass II, MD, PhD, FAAD, is the 2024 recipient of the first-ever Sanofi and Regeneron Diversity, Equity, and Inclusion (DEI) Mid-Career Award, given to support his research into "Genetics, Comorbidities and their Association with Keloids."

Key Points: 
  • A nationally recognized keloids expert, Dr. Glass is an Associate Professor at the University of Texas Southwestern Medical Center in Dallas, Texas.
  • He served as 2021-2022 President of the Skin of Color Society.
  • The Sanofi and Regeneron DEI Mid-Career Award was developed especially for the exceptional mid-career investigator with an established trajectory of excellence in basic, clinical or translational science.
  • Our sincere congratulations to Dr. Glass, the outstanding first award recipient for this highly competitive award—and our sincere gratitude to Sanofi and Regeneron for making the award possible."

WebMD Health Services Announces Strategic Partnership with Verily's Onduo to Enhance Employee Health and Well-Being

Retrieved on: 
星期四, 三月 14, 2024
Health care, Health, Learning, Partnership, Physician, Diabetes, Risk, Patient, Biomarker, Pharmacist, Telehealth, WebMD, Quality of life, Health equity, CDC, Comorbidity, Prediabetes, Hypertension

PORTLAND, Ore., March 14, 2024 /PRNewswire/ -- WebMD Health Services today announced a new partnership with Onduo, a virtual care management solution from Verily, an Alphabet precision health technology company.

Key Points: 
  • PORTLAND, Ore., March 14, 2024 /PRNewswire/ -- WebMD Health Services today announced a new partnership with Onduo, a virtual care management solution from Verily, an Alphabet precision health technology company.
  • This partnership addresses members' needs by combining cutting-edge technology with comprehensive health and well-being solutions.
  • WebMD Health Services will integrate Onduo's virtual care solution into WebMD ONE, a comprehensive health and well-being platform, providing a seamless experience for users.
  • Through this partnership with Onduo, WebMD is expanding how we support members with complex care needs beyond condition management, health coaching and digital programs to include access to devices and telemedicine.

Best Life Insurance Plans for Multiple Sclerosis (MS) Patients - Our Top Picks for 2024

Retrieved on: 
星期二, 三月 12, 2024
Survival, ICC, Patient, History, SBLI, Legal & General, Research, Risk, Policy, Lincoln National Corporation, AEGON, Privacy, Hypertension, Disability, Database, Frontiers Media, Journal, Prescription, Neurosurgery, Roger Hawkins (drummer), MD, Insurance, Diagnosis, Psychiatry, Incidence, Prudential Financial, Mortality, Multiple sclerosis, Mutual, Corebridge Financial, Comorbidity, John Hancock Financial, Pharmaceutical industry

Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.

Key Points: 
  • Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.
  • A small number of people with Multiple Sclerosis experience very mild symptoms and little to no disability.
  • Zieba offered this advice to those with MS who are shopping for life insurance, "MS patients can do a lot to prepare to buy life insurance.
  • Instant life insurance quotes for those with Multiple Sclerosis of all severities are available at www.lifequotes.com .

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
星期二, 三月 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Retrieve Medical Holdings, Inc. Forges Partnership with Louisiana Health System Hospitals

Retrieved on: 
星期一, 二月 26, 2024
Hospital, Roger Hawkins (drummer), Comorbidity, Bed, OTC Markets Group, CMI, Documentation, Emergency department, American College, Emergency, Patient, Retrieval, Partnership, Nursing

The company's wholly owned subsidiary, Retrieve Medical, Inc. ("Retrieve"), has signed a pivotal contract to deploy its cutting-edge software at a prominent Louisiana hospital.

Key Points: 
  • The company's wholly owned subsidiary, Retrieve Medical, Inc. ("Retrieve"), has signed a pivotal contract to deploy its cutting-edge software at a prominent Louisiana hospital.
  • The agreement marks Retrieve's continued expansion into the healthcare landscape, bolstering its portfolio with another esteemed community health system.
  • "We are pleased to broaden our reach into yet another community health system," commented Dr. Mark Rosenberg, Chairman of Retrieve and Past President of the American College of Emergency Physicians.
  • "This partnership underscores our position as the premier provider of physician documentation software for hospitals and medical systems throughout the United States.

2023 in Review: Healthcare Triumphs and the Top Five Trends Shaping Healthcare in 2024

Retrieved on: 
星期三, 一月 31, 2024
Practice Management, Technology, Managed Care, Health, General Health, Mental Health, Health Technology, Software, Artificial Intelligence, Hospitals, Telemedicine, Virtual Medicine, Shift, Comorbidity, Patient satisfaction, University of Connecticut, Social, Intuition, Telehealth, Social determinants of health, Machine learning, Patient, Medicaid, Physical, SDOH, Artificial intelligence, Pharmacy, Community, Organization, Hospital

Bamboo Health , the leader in Real-Time Care Intelligence™, today announced the release of the company’s 2023 Annual Impact Report, outlining the transformative achievements of top healthcare organizations and introducing five key healthcare trends expected in 2024.

Key Points: 
  • Bamboo Health , the leader in Real-Time Care Intelligence™, today announced the release of the company’s 2023 Annual Impact Report, outlining the transformative achievements of top healthcare organizations and introducing five key healthcare trends expected in 2024.
  • In 2023, Bamboo Health impacted 1 billion patient encounters, involving 2,500 hospitals, 8,000 post-acute facilities, 25,000 pharmacies, 32 health plans, 50 state governments and 1 million providers.
  • Jeff Smith, Bamboo Health’s CEO, credited the company's success to its focus on integrating the entire spectrum of patient health needs.
  • To learn more about Bamboo Health’s 2023 successes and the anticipated trends for 2024, view the Annual Impact Report .